Identification of potent, noncovalent fatty acid amide hydrolase (FAAH) inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 21, Issue 8, 2011, Pages 2492-2496

  Gustin, Darin J ^a   Ma, Zhihua ^a   Min, Xiaoshan ^a   Li, Yihong ^a   Hedberg, Christine ^a   Guimaraes, Cris ^a   Porter, Amy C ^a   Lindstrom, Michelle ^a   Lester Zeiner, Dianna ^a   Xu, Guifen ^a   Carlson, Timothy J ^a   Xiao, Shouhua ^a   Meleza, Cesar ^a   Connors, Richard ^a   Wang, Zhulun ^a   Kayser, Frank ^a  

^a AMGEN INC   (United States)

Author keywords

FAAH; FAAH inhibitor; Noncovalent; Structure based design

Indexed keywords

FATTY ACID AMIDASE INHIBITOR; LACTAM; UREA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG PENETRATION; DRUG SYNTHESIS; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; HUMAN TISSUE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

AMIDOHYDROLASES; ANIMALS; BINDING SITES; COMPUTER SIMULATION; CRYSTALLOGRAPHY, X-RAY; ENZYME INHIBITORS; HUMANS; LACTAMS; RATS; SPIRO COMPOUNDS; STRUCTURE-ACTIVITY RELATIONSHIP; UREA;

RATTUS;

EID: 79953283871     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2011.02.052     Document Type: Article

References (51)

1. W.A. Devane, L. Hanus, A. Breuer, R.G. Pertwee, L.a. Stevenson, G. Griffin, D. Gibson, A. Mandelbaum, A. Etinger, and R. Mechoulam Science 258 1992 1946
2. A. Porter, and C.F. Felder Pharmacol. Ther. 90 2001 45
3. S.L. Palmer, G.A. Thakar, and A. Makriyannis Chem. Phys. Lipids 121 2002 3
4. K. Mackie Annu. Rev. Pharmacol. Toxicol. 46 2006 101
5. K. Ahn, M.K. McKinney, and B.F. Cravatt Chem. Rev. 108 2008 1687
6. C.J. Fowler, P.S. Naidu, A. Lichtman, and V. Onnis Br. J. Pharmacol. 156 2009 412
7. M. Seierstad, and J.G. Breitenbucher J. Med. Chem. 51 2008 732
8. M. Maccarrone Curr. Pharm. Des. 12 2006 759
9. B.F. Cravatt, K. Demarest, M.P. Patricelli, M.H. Bracey, D.K. Giang, B.R. Martin, and A.H. Lichtman Proc. Natl. Acad. Sci. U.S.A. 98 2001 937
10. B.F. Cravatt, and A.H. Lichtman Curr. Opin. Chem. Biol. 7 2003 469
11. A.H. Lichtman, D. Leung, C.C. Shelton, A. Saghatelian, C. Hardouin, D.L. Boger, and B.F. Cravatt J. Pharmacol. Exp. Ther. 311 2004 441
12. F.S. Kimball, F.A. Romero, C. Ezzili, J. Garfunkle, T.J. Rayl, D.G. Hochstatter, I. Hwang, and D.L. Boger J. Med. Chem. 51 2008 937
13. Disclosure of OL-135: D.L. Boger, H. Miyauchi, W. Du, C. Hardouin, R.A. Fecik, H. Cheng, I. Hwang, M.P. Hedrick, D. Leung, O. Acevedo, C.R.W. Guimaraes, W.L. Jorgensen, and B.F. Cravatt J. Med. Chem. 48 2005 1849
14. M. Mor, S. Rivara, A. Lodola, P.V. Plazzi, G. Tarzia, A. Duranti, A. Tontini, G. Piersanti, S. Kathuria, and D. Piomelli J. Med. Chem. 47 2004 4998
15. S.G. Kinsey, J.Z. Long, S.T. O'Neal, R.A. Abdulla, J.L. Poklis, D.L. Boger, B.F. Cravatt, and A.H. Lichtman J. Pharmacol. Exp. Ther. 330 2009 902
16. J.A. Palmer, E.S. Higuera, L. Chang, and S.R. Chaplan Neuroscience 154 2008 1554
17. L. Chang, L. Luo, J.A. Palmer, S. Sutton, S.J. Wilson, and A.J. Barbier Br. J. Pharmacol. 148 2006 102
18. X. Wang, K. Sarris, K. Kage, D. Zhang, S.P. Brown, T. Kolasa, C. Surowy, O.F. El Kouhen, S.W. Muchmore, J.D. Brioni, and A.O. Stewart J. Med. Chem. 52 2009 170
19. 50 value for an irreversible inhibitor will be highly dependent on incubation periods.
20. For mechanistic studies of similar piperidinyl-urea based FAAH inhibitors see: Ahn, K.; Johnson, D. S.; Fitzgerald, L. R.; Liimatta, M.; Arendse, A.; Stevenson, T.; Lund, E. T.; Nugent, R. A.; Nomanbhoy, T. K.; Alexander, J. P; Cravatt, B. F. Biochemistry, 2007, 46, 13019. For detailed characterization of 1a see: Keith, J. M.; Apodaca, R.; Xiao, W.; Seierstad, M.; Pattabiraman, K.; Wu, J.; Webb, M.; Karbarz, M. J.; Brown, S.; Wilson, S.; Scott, B.; Tham, C. S.; Luo, L.; Palmer, J.; Wennerholm, M.; Chaplan, S.; Breitenbucher, J. G. Bioorg. Med. Chem. Lett. 2008, 18, 4838.
21. Min, X.; Thibault, S.; Porter, A. C.; Gustin, D. J.; Carlson, Timothy, J.; Xu, H.; Lindstrom, M.; Xu, G.; Uyeda, C.; Ma, Z.; Li, Y.; Kayser, F.; Walker, N. P. C.; Wang, Z. Proc. Natl. Acad. Sci. U. S. A. submitted for publication.
22. For previous co-crystals of FAAH with small molecules see the following reports and references cited therein: M. Mileni, D.S. Johnson, Z. Wang, D.S. Everdeen, M. Liimatta, B. Pabst, K. Bhattacharya, R.A. Nugent, S. Kamtekar, B.F. Cravatt, K. Ahn, and R.C. Stevens Proc. Natl. Acad. Sci. U.S.A. 10535 2008 12820
23. K. Ahn, D.S. Johnson, M. Mileni, D. Beidler, J.Z. Long, M.K. McKinney, E. Weerapana, N. Sadagopan, M. Liimatta, S.E. Smith, S. Lazerwith, C. Stiff, S. Kamtekar, K. Bhattacharya, Y. Zhang, S. Swaney, K. Van Becelaere, R.C. Stevens, and B.F. Cravatt Chem. Biol. 16 2009 411
24. M. Mileni, J. Garfunkle, J.K. DeMartino, B.F. Cravatt, D.L. Boger, and R.C. Stevens J. Am. Chem. Soc. 131 2009 10497
25. M. Mileni, J. Garfunkle, C. Ezzili, F.S. Kimball, B.F. Cravatt, R.C. Stevens, and D.L. Boger J. Med. Chem. 53 2010 230
26. The selectivity of several FAAH inhibitors has been described, see: D.S. Johnson, C. Stiff, S.E. Lazerwith, S.R. Kesten, L.K. Fay, M. Morris, D. Beidler, M.B. Liimatta, S.E. Smith, D.T. Dudley, N. Sadagopan, S.N. Bhattachar, S.J. Kesten, T.K. Nomanbhoy, and B.F. Cravatt ACS Med. Chem. Lett. 2 2010 91
27. D. Zhang, A. Saraf, T. Kolasa, P. Bhatia, G.Z. Zheng, M. Patel, G.S. Lannoye, P. Richardson, A. Stewart, J.C. Rogers, J.D. Brioni, and C.S. Surowy Neuropharmacology 52 2007 1095
28. D. Leung, W. Du, C. Hardouin, H. Cheng, I. Hwang, B.F. Cravatt, and D.L. Boger Bioorg. Med. Chem. Lett. 15 2005 1423
29. The potential for observing idiosyncratic toxicity is generally thought to be mitigated by avoiding covalent modifiers as drug candidates. See: Kumar, S.; Mitra, K.; Kassahun, K.; Baillie, T. A. Adverse Drug Reactions, Handbook of Experimental Pharmacology 196. Springer, Berlin Heidelberg, 2010, p 511. However, predicting adverse events pre-clinically remains difficult and several covalent modifying drugs are approved for use; although in many cases the mechanism of action of these drugs was determined after safety assessments. For leading a reference see: Potashman, M. H.; Duggan, M. E. J. Med. Chem. 2009, 52, 1233.
30. C.J. Farady, C.S. Craik, Encyclopedia of Chemical Biology 2009 John Wiley & Sons Hoboken, NJ 49 60
31. J. Zhong, and W.C. Groutas Curr. Top. Med. Chem. 4 2004 1203
32. B.E. Maryanoff J. Med. Chem. 2003 769
33. J.C. Powers, J.L. Asgian, O.D. Ekici, and K.E. James Chem. Rev. 102 2002 4639
34. Version 4.5, Schrödinger, LLC, New York, NY, 2007.
35. In each case, spectral data (NMR and LCMS) obtained was consistent with the assigned structure. Compounds were purified by chromatography to a purity of >95% AUC as determined by analytical HPLC. Optically active compounds were >97% ee.
36. M. Colombo, M. Gigilo, and I. Peretto J. Heterocycl. Chem. 454 2008 1077
37. T. Ruckle, M. Biamonte, T. Grippi-Vallotton, S. Arkinstall, Y. Cambet, M. Camps, C. Chabert, D.J. Church, S. Halazy, X. Jiang, A. Nichols, W. Sauer, and J.-P. Grotteland J. Med. Chem. 47 2004 6921
38. C.S. Burgey, C.A. Stump, D.N. Nguyen, J.Z. Deng, A.G. Quigley, B.R. Norten, I.M. Bell, S.D. Mosser, C.A. Salvatore, R.Z. Rutledge, S.A. Kane, K.S. Koblan, J.P. Vacca, S.L. Graham, and T.L. Williams Bioorg. Med. Chem. Lett. 16 2006 5052
39. H. Ueno, K. Yokota, J.I. Hoshi, K. Yasue, M. Hayashi, Y. Hase, I. Uchida, K. Aisaka, S. Katoh, and H. Cho J. Med. Chem. 48 2005 3586
40. K. Qian, L. Wang, C.L. Cywin, B.T.II. Farmer, E. Hickey, C. Homon, S. Jakes, M.A. Kashem, G. Lee, S. Leonard, J. Li, R. Magboo, W. Mao, E. Pack, C. Peng, A.III. Prokopowicz, M. Welzel, J. Wolak, and T. Morwick J. Med. Chem. 52 2009 1814
41. Katamreddy, S R.; Caldwell, R. D.; Heyer, D.; Samano, V.; Thompson, J. B.; Carpenter, A. J.; Conlee, C. R.; Boros, E. E.; Thompson, B. D. PCT Int. Appl. WO2008008887, 2008
42. Z. Pei, L. Xiaofeng, T.W. von Geldern, K. Longenecker, D. Pireh, K.D. Stewart, B.J. Backes, C. Lai, T.H. Lubben, S.J. Ballaron, D.W.A. Beno, A.J. Kempf-Grote, H.L. Sham, and J.M. Trevillyan J. Med. Chem. 50 2007 1983
43. R.A. Copeland, Evaluation of Enzyme Inhibitors in Drug Discovery 2005 John Wiley & Sons Hoboken, NJ 125 128
44. J.P. Alexander, and B.F. Cravatt Chem. Biol. 12 2005 1179
45. Battista, K. A. Bignan, G. C.; Connolly, P. J. Middleton, S. A.; Orsini, M. J.; Liu, J. L.; Reitz, A. B. PCT Int. Appl. 2007050381, 2007.
46. J. Perregaard, J. Arnt, K.P. Boegesoe, J. Hyttel, and C. Sanchez J. Med. Chem. 35 1992 1092
47. E. Desarbe, S. Coudret, C. Meheust, and J.-Y. Merour Tetrahedron 53 1997 3637
48. L. Huang, L. Berry, S. Ganga, B. Janosky, A. Chen, J. Roberts, A.E. Colletti, and M.-H.J. Lin Drug Metab. Dispos. 38 2010 223
49. L. Xu, Y. Chen, Y. Pan, G.L. Skiles, and M. Shou Drug Metab. Dispos. 10 2009 2330
50. Also see: Q. Wang, J.D. Rager, K. Weinstein, P.S. Kardos, G.L. Dobson, J. Li, and I.J. Hidalgo Int. J. Pharm. 288 2005 349
51. C.L. Schaffer Annu. Rep. Med. Chem. 45 2010 10